Compare MCY & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCY | BLTE |
|---|---|---|
| Founded | 1961 | 2018 |
| Country | United States | United States |
| Employees | 4300 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.0B |
| IPO Year | 1995 | 2021 |
| Metric | MCY | BLTE |
|---|---|---|
| Price | $103.62 | $147.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $228.89 |
| AVG Volume (30 Days) | ★ 222.9K | 133.0K |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.19% | N/A |
| EPS Growth | ★ 15.62 | N/A |
| EPS | ★ 8.20 | N/A |
| Revenue | ★ $5,992,468,000.00 | N/A |
| Revenue This Year | $4.51 | N/A |
| Revenue Next Year | $6.66 | N/A |
| P/E Ratio | $13.02 | ★ N/A |
| Revenue Growth | ★ 9.44 | N/A |
| 52 Week Low | $74.29 | $90.84 |
| 52 Week High | $113.06 | $200.00 |
| Indicator | MCY | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 39.67 |
| Support Level | $100.24 | $145.21 |
| Resistance Level | $103.94 | $161.08 |
| Average True Range (ATR) | 1.96 | 5.89 |
| MACD | 0.40 | -0.37 |
| Stochastic Oscillator | 44.19 | 30.70 |
Mercury General Corp is an insurance holding company. It is engaged in writing personal automobile insurance and provides related property and casualty insurance products. The company offers the following types of automobile coverage: collision, property damage, bodily injury (BI), comprehensive, personal injury protection (PIP), underinsured and uninsured motorist, and other hazards. Additionally, it offers the following types of homeowners coverage: dwelling, liability, personal property, and other coverages. The company has one reportable business segment, the Property and Casualty business segment.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.